Merck & Company (MRK) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Merck & Company (MRK)

119.60

+0.08 (0.07%)

as of Jun 9, 2026, 8:00:00 pm Market Open.

310 watching

Investor Insights

Jun 9, 2026, 12:00 am

This summary was created by AI, based on 21 opinions in the last 12 months.

Merck & Company (MRK) is widely recognized for its robust drug pipeline, particularly in the oncology space, despite concerns surrounding the impending patent expiration of its blockbuster drug Keytruda in 2028, which currently accounts for a significant portion of its revenue. Experts express mixed sentiments on its future performance; while some highlight the strong growth prospects from various drugs in the pipeline and strategic acquisitions, others point to risks and valuation concerns in light of the upcoming patent cliff. Analysts have shown optimism regarding MRK's capacity to sustain revenue growth post-Keytruda, often citing its decent dividend yield and potential for substantial upside. Overall, the company has been recommended as a solid investment, with a call for cautious management of positions amid broader market uncertainty and clarity on US drug pricing affecting the pharmaceutical sector.

Consensus

Bullish

Valuation

Undervalued

Similar

Pfizer, PFE

TOP PICK

Yield is over 3%. Trading around 15 X next year's earnings.

TOP PICK

This late in the cycle, look for stocks that are large, overlooked and underowned. Had a low in 2002 and a higher low at the end of 2003 in a downtrend, still expects to see money going to this group.

WEAK BUY

Have more patent issues than the majority of the big pharmas. Not a lot of catalysts. If you are a real long-term, patient investor, not a bad buy.

BUY

Big pharma stocks should do well in this market. Historically, they do well when rates start to move up.

DON'T BUY

Still under a major downtrend line. Trying to find a base.

TOP PICK

A quiet stock in that not many people are expecting much from them, 7/8% growth this year but you do get a nice 3%+ dividend yield while you wait. Trades at about 15 X earnings. Has a new cholesterol drug coming out this year.

BUY

Has had problems with patent expiry's and drugs in its channel. Gives a 3% dividend yield. Continues to like.

TOP PICK

trading at significantly less than fair value. Bad news on drug development. Dividends at 3.3%

DON'T BUY

Have had tremendous issues. They had to stop production on a couple of drugs that were being tested. Virtually no revenue or earnings coming.

DON'T BUY

When the stock is not participating in a bull market, steer clear. A strong Company and well financed with good products but there is no real excitement. If the market rolls over, it would get hit hard.

BUY

Likes some of the major pharmaceuticals at these levels. Very cheap. Buy and hold.

STRONG BUY

A fantastic time to be buying this stock. If the pharmaceutical industry reverts to anything near normal, this is a huge screaming buy.

BUY

Missed its numbers. Demographics for drugs looks great. At a great price.

DON'T BUY

Not a fan. They don't have a very strong pipeline of promising drugs. Present drugs are facing competition from generics.

TOP PICK

Trading at a significant discount.Has been getting left behind.

Showing 256 to 270 of 304 entries

Wealthica The ultimate 360° Tracker Your financial life in one place, automatically

Most Recent Experts

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Barry Schwartz

Baskin Wealth Management

Jim Cramer - Mad Money

CNBC

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

Mike Vinokur, CFA, CMT, and CFP

Propellus Wealth Partners/iA Private Wealth

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Merck & Company (MRK)